3?446. 71. Schnitzer TJ, Hochberg MC, Marrero CE, Duquesroix B, Frayssinet H, Beekman M: Efficacy and security of naproxcinod in individuals with osteoarthritis with the knee: a 53-week potential randomized multicenter study. Semin Arthritis Rheum 2011, 40:285?97. 72. Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B: Efficacy and safety of naproxcinod in the remedy of patients with osteoarthritis of your knee: a 13-week prospective, randomized, multicenter study. Osteoarthr Cartil 2010, 18:629?39. 73. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS: Efficacy and tolerability of lumiracoxib within the therapy of osteoarthritis in the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 2005, 27:64?7. 74. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG: The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in sufferers with hypertension, osteoarthritis, and form two diabetes mellitus. Arch Intern Med 2005, 165:161?68. 75. Tannenbaum H, Berenbaum F, Reginster J-Y, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A: Lumiracoxib is effective in the remedy of osteoarthritis on the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 2004, 63:1419?426. 76. Vojtass J, Vojtass J, Jacobs A, Rynn L, Waechter S, Richarz U: A phase iiib, multicentre, randomised, parallel-group, placebo-controlled, double-blind study to investigate the efficacy and safety of oros hydromorphone in subjects with moderate-to-severe chronic pain induced by osteoarthritis with the hip or the knee. Discomfort Res Treat 2011, 2011:239501. 77. Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BA, Aversano ML, Reicin AS: Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of individuals with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:470?79. 78. Higgins J, Thompson SG: Quantifying heterogeneity inside a meta-analysis. Stat Med 2002, 21:1539?558. 79. Higgins JPT, Green S: (editors) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.Buy2460255-78-9 1.36234-66-9 manufacturer 0.PMID:23600560 Wiley On the web Library; 2011. cochrane-handbook.org. 80. Spiegelhalter D, Greatest N, Carlin B, Van Der Linde A: Bayesian measures of model complexity and match (with discussion). J R Stat Soc 2002, 64:583?16. Series B. 81. Corrigan R, Derry S, Wiffen PJ, Moore RA: Clonazepam for neuropathic discomfort and fibromyalgia in adults. Cochrane Database Syst Rev 2012(five), CD009486. DOI: ten.1002/14651858.CD009486.pub2. 82. National Collaborating Centre for Chronic Circumstances: Osteoarthritis: National Clinical Guideline for Care and Management in Adults. Appendix D. London: Royal College of Physicians; 2008. 83. Choy E, Marshall D, Gabriel ZL, Mitchell SA: Gylee E. A systematic overview and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Seminars in Arthritis and Rheumatism: Dakin HA; 2011. 84. Quilici S, Chancellor J, L hgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B: Meta-analysis of duloxetine vs. pregabalin and gabapentin within the treatment of diabetic peripheral neuropathic discomfort. BMC Neurol 2009, 9:six. 85. Trijau S, Avouac J, Escalas C, Gossec L, Dougados M: Influence of flare style on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysi.